Madrigal Pharmaceuticals (MDGL) Accounts Payables (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Accounts Payables data on file, last reported at $60.8 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $60.8 million, up 44.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.8 million (up 44.57% YoY), and the FY2025 annual result was $48.9 million, up 12.11% from the prior year.
• Accounts Payables climbed to $60.8 million in Q1 2026 per MDGL's latest filing, from $48.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $60.8 million in Q1 2026 and troughed at $9.0 million in Q2 2024.
• A 5-year average of $29.7 million and a median of $23.8 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 958.48% in 2022, then tumbled 48.71% in 2024.
• A 5-year view of Accounts Payables shows it stood at $23.8 million in 2022, then advanced by 17.67% to $28.0 million in 2023, then jumped by 55.48% to $43.6 million in 2024, then advanced by 12.11% to $48.9 million in 2025, then grew by 24.39% to $60.8 million in 2026.
• Business Quant data shows MDGL's Accounts Payables at $60.8 million in Q1 2026, $48.9 million in Q4 2025, and $44.9 million in Q3 2025.